| Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer APDA Bom, LP Rangel, DCF Costa, GAP de Oliveira, D Sanches, ... Journal of Biological Chemistry 287 (33), 28152-28162, 2012 | 302 | 2012 |
| Prion-like aggregation of mutant p53 in cancer JL Silva, CVDM Gallo, DCF Costa, LP Rangel Trends in biochemical sciences 39 (6), 260-267, 2014 | 207 | 2014 |
| The aggregation of mutant p53 produces prion-like properties in cancer LP Rangel, DCF Costa, TCRG Vieira, JL Silva Prion 8 (1), 75-84, 2014 | 122 | 2014 |
| Aggregation and prion-like properties of misfolded tumor suppressors: is cancer a prion disease? DCF Costa, GAP de Oliveira, EA Cino, IN Soares, LP Rangel, JL Silva Cold Spring Harbor perspectives in biology 8 (10), a023614, 2016 | 88 | 2016 |
| p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells LP Rangel, GDS Ferretti, CL Costa, SMMV Andrade, RS Carvalho, ... Journal of Biological Chemistry 294 (10), 3670-3682, 2019 | 79 | 2019 |
| Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor JL Silva, LP Rangel, DCF Costa, Y Cordeiro, CV De Moura Gallo Bioscience reports 33 (4), e00054, 2013 | 79 | 2013 |
| Resveratrol prevents p53 aggregation in vitro and in breast cancer cells DCF da Costa, NPC Campos, RA Santos, FH Guedes-da-Silva, ... Oncotarget 9 (49), 29112, 2018 | 68 | 2018 |
| Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain PS Kovachev, D Banerjee, LP Rangel, J Eriksson, MM Pedrote, ... Journal of Biological Chemistry 292 (22), 9345-9357, 2017 | 56 | 2017 |
| Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein G Valdameri, L Pereira Rangel, C Spatafora, J Guitton, C Gauthier, ... ACS chemical biology 7 (2), 322-330, 2012 | 56 | 2012 |
| Anticancer potential of resveratrol, β-lapachone and their analogues DC Ferraz da Costa, L Pereira Rangel, MMDC Martins-Dinis, GDS Ferretti, ... Molecules 25 (4), 893, 2020 | 51 | 2020 |
| Misfolding, aggregation, and disordered segments in c-Abl and p53 in human cancer GAP de Oliveira, LP Rangel, DC Costa, JL Silva Frontiers in Oncology 5, 97, 2015 | 51 | 2015 |
| Bioactive compounds and metabolites from grapes and red wine in breast cancer chemoprevention and therapy DC Ferraz da Costa, L Pereira Rangel, J Quarti, RA Santos, JL Silva, ... Molecules 25 (15), 3531, 2020 | 41 | 2020 |
| Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells NM Dos Santos, GAP de Oliveira, MR Rocha, MM Pedrote, ... Journal of Biological Chemistry 294 (24), 9430-9439, 2019 | 39 | 2019 |
| Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion JL Silva, TCRG Vieira, MPB Gomes, LP Rangel, SMN Scapin, Y Cordeiro Methods 53 (3), 306-317, 2011 | 34 | 2011 |
| RNA modulates aggregation of the recombinant mammalian prion protein by direct interaction PS Kovachev, MPB Gomes, Y Cordeiro, NC Ferreira, LPF Valadão, ... Scientific reports 9 (1), 12406, 2019 | 32 | 2019 |
| Isolation of two bioactive diterpenic acids from Copaifera glycycarpa oleoresin by high‐speed counter‐current chromatography PA De Souza, LP Rangel, SS Oigman, MM Elias, A Ferreira‐Pereira, ... Phytochemical analysis 21 (6), 539-543, 2010 | 30 | 2010 |
| New structure–activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity LP Rangel, E Winter, C Gauthier, R Terreux, LD Chiaradia-Delatorre, ... Drug design, development and therapy, 1043-1052, 2013 | 29 | 2013 |
| Recent synthetic approaches towards small molecule reactivators of p53 JL Silva, CGS Lima, LP Rangel, GDS Ferretti, FP Pauli, RCB Ribeiro, ... Biomolecules 10 (4), 635, 2020 | 26 | 2020 |
| Inhibitory effects of gallic acid ester derivatives on Saccharomyces cerevisiae multidrug resistance protein Pdr5p L Pereira Rangel, M Fritzen, RA Yunes, PC Leal, TB Creczynski-Pasa, ... FEMS yeast research 10 (3), 244-251, 2010 | 24 | 2010 |
| Oroidin inhibits the activity of the multidrug resistance target Pdr5p from yeast plasma membranes FR da Silva, AC Tessis, PF Ferreira, LP Rangel, AS Garcia-Gomes, ... Journal of natural products 74 (2), 279-282, 2011 | 22 | 2011 |
